Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.3800 (-4.27%) ($5.3800 - $5.3800) on Fri. Jul. 2, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.68% (three month average) | RSI | 59 | Latest Price | $5.3800(-4.27%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 1.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IPO(87%) ICLN(48%) XOP(39%) IWC(37%) XBI(41%) | Factors Impacting ADMS price | ADMS will decline at least -1.84% in a week (0% probabilities). BLOK(10%) DRIV(7%) XLV(-18%) XLRE(-22%) INDA(-64%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.84% (StdDev 3.68%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.32(1.13%) | 10 Day Moving Average | $5.29(1.7%) | 20 Day Moving Average | $5.2(3.46%) | To recent high | -8.3% | To recent low | 7.4% | Market Cap | $152m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |